Health Condition 1: G35- Multiple sclerosis
Conditions
Interventions
Intervention1: SAR442168 60 mg or Placebo matched to SAR442168: Dose formulation Tablet
Unit dose strength(s) 60 mg
Dosage level(s) Once daily
Route of administration Oral
IMP
approximately 36 mo
Sponsors
Sanofi Healthcare India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Age I 01. The participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent. Type of participant and disease characteristics I 02. The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria (16). I 03. The participant has an EDSS score �5.5 at the first Screening Visit I 04. The participant must have at least 1 of the following prior to screening: �1 documented relapse within the previous year OR �2 documented relapses within the previous 2 years, OR �1 documented Gd-enhancing brain lesion on an MRI scan within the previous year. Note: The initial clinical demyelinating episode of MS should be counted as a relapse for the first 2 criteria Weight I 05. Not applicable. Sex I 06. Male or Female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants wishing to conceive a child and female participants becoming pregnant or wishing to become pregnant must permanently discontinue the study intervention and follow the local teriflunomide label recommendation A) Male participants Male participants are eligible to participate if they agree to the following during the intervention period and until the accelerated elimination procedure is performed. Refrain from donating sperm Plus either: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier method as detailed below Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant B) Female participants A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions apply: Is not a WOCBP OR Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during the study and after study intervention are located in the schedule of activities (SoA) The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy, if allowed by local regulations. See protocol for country-specific contraception requirements Informed Consent I 07.
Exclusion criteria
Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: Medical conditions E 01. The participant has been diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria or with nonrelapsing SPMS. E 02. The participant has a history of infection or may be at risk for infection: A history of T-lymphocyte or T-lymphocyte-receptor vaccination, transplantation (including solid organ, stem cell, and bone marrow transplantation) and/or antirejection therapy The participant has received any live (attenuated) vaccine (including but not limited to varicella zoster, oral polio, and nasal influenza) within 2 months before the first treatment visit. E 03. The presence of psychiatric disturbance or substance abuse as evidenced by: A history of any psychiatric disease, behavioral condition, or depression requiring hospitalization within 2 years prior to the Screening Visit E 04. The following findings obtained during the screening visit considered in the Investigatorââ?¬•s judgment to be clinically significant: Any screening laboratory values outside normal limits. Abnormal ECG. E 05. Conditions that may predispose the participant to excessive bleeding: A bleeding disorder or known platelet dysfunction at any time prior to the Screening Visit. A platelet count E 06. Conditions that would adversely affect participation in the study or make the primary efficacy endpoint non-evaluable: Any malignancy within 5 years prior to the Screening visit (except for effectively treated carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell carcinoma of the skin) will also be exclusionary. Prior/concomitant therapy E 07. The participant has received any of the following medications/treatments within the specified time frame before any baseline assessment (no washout is required for interferon beta or glatiramer acetate treatments): E 08. The participant is receiving strong inducers or inhibitors of cytochrome P450 (CYP) 3A or CYP2C8 hepatic enzymes as listed in Appendix 8A E 09. The participant is receiving anticoagulant/antiplatelet therapies, including: Acetylsalicylic acid (aspirin) Antiplatelet drugs (eg, clopidogrel) Warfarin (vitamin K antagonist) Apixaban, edoxaban, rivaroxaban (direct factor Xa inhibitors) Prior/concurrent clinical study experience E 10. The participant was previously exposed to any BTK inhibitor, including SAR442168. E 11. The participant has taken other investigational drugs within 3 months or 5 half-lives, whichever is longer, before the Screening Visit. Diagnostic assessments E 12. The participant has had a relapse in the 30 days prior to randomization. Other exclusions E 13. Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized. E 14. Any country-related specific regulation that would prevent the participant from entering the study. E 15. Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures or not able to follow the schedule of protocol asse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annualized adjudicated relapse rate (ARR) during the study period assessed by confirmed protocol-defined adjudicated relapsesTimepoint: Study will continue until 162 events are projected to have occurred in the pooled data, to ensure approximately 90% power to detect a 40% risk reduction in 6-month CDW with SAR442168 compared to teriflunomide, based on an assumed 24-month event rate of 12% in the teriflunomide arm. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to onset of confirmed disability worsening (CDW), confirmed over at least 6 months, defined as follows: increase of ââ?°Â¥1.5 points from the baseline Expanded Disability Status Scale (EDSS) score when the baseline score is 0, OR increase of ââ?°Â¥1.0 point from the baseline EDSS score when the baseline score is 0.5 to ââ?°Â¤5.5, OR increase of ââ?°Â¥0.5 point from the baseline EDSS score when the baseline score is 5.5 Timepoint: at least 6 months;Time to onset of CDW, assessed by the EDSS score and confirmed over at least 3 months Timepoint: at least 6 months | — |
Countries
Argentina, Brazil, France, Germany, India, Netherlands, Portugal, Republic of Korea, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom, United States of America
Contacts
Public ContactDhara Patel
Sanofi Healthcare India Private Limited
Outcome results
None listed